Patient stratification of two asthma populations reveal distinct genetic and mechanistic differences
European Respiratory Society Congress 2024
Authors: Colin Stubberfield, Krystyna Taylor, Sayoni Das, Matthew Pearson, Jim Kozubek, Steve Gardner 
Patient stratification of two asthma populations reveal distinct genetic and mechanistic differences between T2-high and T2-low asthma
PrecisionLife prioritize 10 of the most tractable novel gene targets specific to T2-low asthma in both UK Biobank and GASP asthma populations
Using patients with blood eosinophil data from UK Biobank, PrecisionLife identified genetic differences between T2-high and T2-low asthma cohorts with clear differences in biological processes; genes associated with T2-high asthma regulate T2-driven allergic immune pathways, whereas patients with T2-low asthma have combinations of variants associated with neutrophilic inflammation, apoptosis, metal ion binding and lipid metabolism.
In 2024, we accessed a secondary population derived from the GASP (Genetics of Asthma Severity and Phenotypes) study.
Analysis of genotype data recapitulated our findings from UK Biobank, confirming the genetic differences between T2-high and T2-low asthma and validating 10 shortlisted drug targets in T2-low asthma.
The targets are novel and have strong mechanism of action hypotheses in T2-low asthma development. These can be used for the development of more targeted and efficient treatment strategies to improve asthma control in each endotype.
